Imperva Inc (NYSE:IMPV) has been given a consensus rating of “Buy” by the twenty-four analysts that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $51.25.
Several research analysts have commented on IMPV shares. UBS AG started coverage on Imperva in a report on Tuesday, June 6th. They set a “positive” rating and a $60.00 target price on the stock. Evercore ISI set a $56.00 target price on Imperva and gave the stock a “buy” rating in a report on Thursday, August 10th. BidaskClub downgraded Imperva from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Zacks Investment Research raised Imperva from a “hold” rating to a “strong-buy” rating and set a $52.00 target price on the stock in a report on Wednesday, August 2nd. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $47.00 target price on shares of Imperva in a report on Friday, July 14th.
A number of hedge funds have recently modified their holdings of the stock. ETF Managers Group LLC purchased a new stake in shares of Imperva during the second quarter worth approximately $41,888,000. North Run Capital LP raised its stake in shares of Imperva by 999.3% in the first quarter. North Run Capital LP now owns 750,000 shares of the software maker’s stock worth $30,788,000 after buying an additional 681,772 shares in the last quarter. Clearbridge Investments LLC raised its stake in shares of Imperva by 47.0% in the first quarter. Clearbridge Investments LLC now owns 1,262,507 shares of the software maker’s stock worth $51,826,000 after buying an additional 403,809 shares in the last quarter. BlackRock Inc. raised its stake in shares of Imperva by 11.3% in the second quarter. BlackRock Inc. now owns 2,124,043 shares of the software maker’s stock worth $101,635,000 after buying an additional 215,170 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Imperva by 8,392.3% in the first quarter. BNP Paribas Arbitrage SA now owns 200,927 shares of the software maker’s stock worth $8,248,000 after buying an additional 198,561 shares in the last quarter. 92.72% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece of content was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/08/15/brokerages-set-imperva-inc-impv-price-target-at-50-19-updated-updated-updated.html.
Imperva (NYSE IMPV) opened at 43.70 on Monday. The firm has a 50-day moving average price of $47.45 and a 200-day moving average price of $45.41. The firm’s market cap is $1.48 billion. Imperva has a 1-year low of $34.40 and a 1-year high of $57.24.
Imperva (NYSE:IMPV) last issued its quarterly earnings results on Thursday, July 27th. The software maker reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.05 by $0.15. Imperva had a negative net margin of 4.69% and a negative return on equity of 5.00%. The business had revenue of $74.44 million during the quarter, compared to the consensus estimate of $74.30 million. During the same quarter in the previous year, the business posted ($0.23) EPS. The company’s revenue for the quarter was up 28.6% on a year-over-year basis. On average, analysts expect that Imperva will post $0.81 earnings per share for the current fiscal year.
About Imperva
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with MarketBeat.com's FREE daily email newsletter.
